Tags

Type your tag names separated by a space and hit enter

Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine.
Clin Immunol 2010; 136(2):228-35CI

Abstract

Yearly influenza vaccination is recommended for patients with humoral primary immunodeficiency (hPID). However, humoral responses following vaccination can be expected to be reduced in these patients. The efficacy of influenza vaccination in patients with hPID, anti-influenza antibody responses was assessed in 26 patients with hPID and 26 matched healthy controls (HC) using hemagglutination inhibition assay. Following vaccination, geometric mean titers (GMT) significantly increased for all influenza strains in the HC group, but only for A/H1N1 in the patient group. Fold increase in anti-influenza titer and seroprotection rates were lower for patients than for HC for A/H3N2 and A/H1N1, leading to postvaccination titer > or =40 in only 29% and 83% vs. 77% and 100%, respectively. Previous vaccination in patients and treatment with IVIg did not result in a higher rate of postvaccination titer > or =40. In conclusion, patients with hPID show hardly any humoral response following influenza vaccination.

Authors+Show Affiliations

Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. s.van.assen@int.umcg.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20421178

Citation

van Assen, Sander, et al. "Patients With Humoral Primary Immunodeficiency Do Not Develop Protective Anti-influenza Antibody Titers After Vaccination With Trivalent Subunit Influenza Vaccine." Clinical Immunology (Orlando, Fla.), vol. 136, no. 2, 2010, pp. 228-35.
van Assen S, Holvast A, Telgt DS, et al. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol. 2010;136(2):228-35.
van Assen, S., Holvast, A., Telgt, D. S., Benne, C. A., de Haan, A., Westra, J., ... Bijl, M. (2010). Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clinical Immunology (Orlando, Fla.), 136(2), pp. 228-35. doi:10.1016/j.clim.2010.03.430.
van Assen S, et al. Patients With Humoral Primary Immunodeficiency Do Not Develop Protective Anti-influenza Antibody Titers After Vaccination With Trivalent Subunit Influenza Vaccine. Clin Immunol. 2010;136(2):228-35. PubMed PMID: 20421178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. AU - van Assen,Sander, AU - Holvast,Albert, AU - Telgt,Denise S C, AU - Benne,Cornelis A, AU - de Haan,Aalzen, AU - Westra,Johanna, AU - Kallenberg,Cees G M, AU - Bijl,Marc, Y1 - 2010/04/24/ PY - 2009/08/21/received PY - 2010/03/19/revised PY - 2010/03/29/accepted PY - 2010/4/28/entrez PY - 2010/4/28/pubmed PY - 2010/8/6/medline SP - 228 EP - 35 JF - Clinical immunology (Orlando, Fla.) JO - Clin. Immunol. VL - 136 IS - 2 N2 - Yearly influenza vaccination is recommended for patients with humoral primary immunodeficiency (hPID). However, humoral responses following vaccination can be expected to be reduced in these patients. The efficacy of influenza vaccination in patients with hPID, anti-influenza antibody responses was assessed in 26 patients with hPID and 26 matched healthy controls (HC) using hemagglutination inhibition assay. Following vaccination, geometric mean titers (GMT) significantly increased for all influenza strains in the HC group, but only for A/H1N1 in the patient group. Fold increase in anti-influenza titer and seroprotection rates were lower for patients than for HC for A/H3N2 and A/H1N1, leading to postvaccination titer > or =40 in only 29% and 83% vs. 77% and 100%, respectively. Previous vaccination in patients and treatment with IVIg did not result in a higher rate of postvaccination titer > or =40. In conclusion, patients with hPID show hardly any humoral response following influenza vaccination. SN - 1521-7035 UR - https://www.unboundmedicine.com/medline/citation/20421178/Patients_with_humoral_primary_immunodeficiency_do_not_develop_protective_anti_influenza_antibody_titers_after_vaccination_with_trivalent_subunit_influenza_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6616(10)00530-9 DB - PRIME DP - Unbound Medicine ER -